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Abstract 
Objective: To compare the efficacy of Oral Ivermectin with Permethrin 1% Shampoo in the treatment of 
Pediculosis Capitis. 
Materials and Methods: This Randomized controlled trial was conducted at the Department of Dermatology, 
Bolan Medical College Quetta from December 24, 2016, to June 23, 2017. All children of either gender having age 5 
and above weight, more than 15 kg presented with head-lice infestation confirmed by combing the wet hair with a 
fine-toothed detection comb were enrolled. All patients were randomly allocated into two groups. Patients in 
group A received oral Ivermectin in a dose of 200mcg/kg while patients in group B received an application of 1% 
Permethrin Shampoo. They were called after one week and they received a second dose of oral Ivermectin in the 
same dose of 200mcg/kg and application of Permethrin 1% Shampoo and re-evaluated after one week. Treatment 
was considered effective by the absence of live lice by day 15 of treatment. 
Results: The majority of the patients presented were females in both groups, i.e. 20 (66.7%) and 23 (76.7%) 
respectively. An insignificant difference was observed in the mean age in the between-group (p-value=0.482). 
Efficacy was found significantly higher in oral Ivermectin group 26 (86.7%) as compared to 1% Permethrin 
Shampoo (P-value <0.001). 
Conclusion: The efficacy of the oral Ivermectin group was considerably higher as compared to 1% Permethrin 
Shampoo in our cohort. 
Keywords: Pediculosis, Oral Ivermectin, 1% topical Permethrin. 
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Introduction 
 
Head lice infestation (Pediculosis Capitis) is a 
condition caused by an infestation of the hair and 
scalp by Pediculus Humanus Capitis (the head louse).1 
It is an important public health problem mainly 
affecting school-going children of 8-11 years of age.2 In 
Europe prevalence varied from 1-20%.1 In developing 
countries, prevalence up to 40% has been observed.3 
Mostly seen in people with poor hygiene and low 
socioeconomic status.1,4,5 
Pediculosis Capitis is a contagious infestation and an 
infected person can commonly spread it through direct 
head to head contact. The head louse sucks blood from 
the human scalp 4-5 times per day and injects saliva 
into the scalp which causes pruritis. The resulting 
repeated scratching leads to loss of hair integrity and 
secondary bacterial infections and reactive Cervical 
and Occipital Lymphadenopathy.6 
Head louse infestation can be easily diagnosed by 
inspecting the hair and scalp or by dry/wet combing.  
However, the superior method is wet combing.7 The 
nits can be seen in the occipital and post-auricular 
regions.6 
Treatment options include manual removal (using wet 
comb and conditioner).8 Topical medications include 
neurotoxic drugs including permethrin, malathion, 
phenothrin and carbaryl,9 lindane,10 benzyl alcohol 
5%,11 spinosad,12  dimeticone13, and oral medication 
such as ivermectin. 
Permethrin is a synthetic drug which acts as a 
neurotoxin.  It belongs to the pyrethroids neurotoxin 
family which affects voltage-sensitive Na+ channels of 
the nervous system of the insect, causing 
depolarization of the nerve resulting in 
hyperexcitation followed by muscle paralysis and 
ultimately death of the parasite. In a study performed 
by Ian F Burgess et al the efficacy of 1% Permethrin 
was found out to be 14.9% when compared to 
Dimeticone.13 
Antiparasitic drug Ivermectin binds to glutamate-
gated chloride ion channels in invertebrates and 
interrupts neurotransmission can be used to treat 
conditions such as lymphatic filariasis, helminthiases, 
onchocerciasis, and ectoparasite infestations, mainly 
scabies.14 
The dose of oral ivermectin in pediculosis capitis is 
200mcg/kg, which is repeated after one week. 
Ivermectin is a safe drug however it can cross the 
blood-brain barrier and cause neurotoxicity in children 
with weight less than 15 kg and in pregnant and 
breastfeeding mothers.15 A study conducted by Ameen 
et al on oral ivermectin for pediculosis capitis showed 
efficacy of 93%.14 
The rationale behind my study was that to date only 
topical medications have been used in the local 
population, which are messy to use and resistance to 
topical medications has been reported.16 Ivermectin is 
the only oral pediculicide drug available for 
pediculosis capitis. However, no local or national 
study on the efficacy of oral Ivermectin has been 
performed to date and therefore it is not used 
routinely in our department by health professionals. 
Rather the patients are treated with topical Permethrin 
for pediculosis capitis. 
 
Materials and Methods 
 
This Randomized controlled trial was conducted at the 
Department of Dermatology, Bolan Medical College/ 
Sandeman Provincial Hospital, Quetta. The study 
duration was 6 months. The sampling technique used 
was Consecutive (non-probability). The sample size 
calculated is 10, five in each group, keeping efficacy of 
Permethrin as 14.9%, the efficacy of Ivermectin as 93%, 
confidence level 95%, and power of the test 90%. Since 
the sample size is very small so it was increased to 30 
in each group and the total sample size was 60 
patients. 
Sample Selection: 
Inclusion Criteria: 
1. Both genders. 
2. Age 5 and above. 
3. Weight more than 15 kg.  Since the safety of 
this drug in patients weighing below 15 kg has 
yet not been established. 
4. Head-lice infestation (defined as the presence 
of live lice) is confirmed by combing the wet 
hair with a fine-toothed detection comb. 
Exclusion Criteria: 
1. Pregnancy or breastfeeding. Since Ivermectin 
is a category c drug and can be excreted in 
breast milk. 
2. Use of any pediculicidal treatment or any 
potentially interacting drug within the 2 
weeks before treatment. 
3. A hairstyle (e.g.; tight plaiting) that may cause 
difficulty in combing. 
The above mentioned are confounders and not 
included in the study to reduce bias. 
Data Collection Procedure: 
The study was conducted after getting approval from 
the hospital’s ethical and research committee. All 
patients meeting the inclusion criteria with active head 
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louse infestation were included in the study 
throughout the patient department. The purpose and 
benefits of the study were explained to the patient and 
they were assured that the study is done purely for 
data publication and research purpose and written 
informed consent was obtained. All patients were 
subjected to detailed history and physical examination 
and they were diagnosed with active louse infestation 
by visual inspection of hair and wet hair combing. 
Ethical issues were addressed and confidentiality was 
maintained and during an examination, patient 
comfort was taken care of. All patients were randomly 
allocated into two groups. Patients in group A 
received oral Ivermectin in a dose of 200 mcg/kg 
while patients in group B received an application of 
1% Permethrin Shampoo. They were called after one 
week and they received a second dose of oral 
Ivermectin in the same dose of 200 mcg/kg and 
application of 1% Permethrin Shampoo and re-
evaluated after one week. Treatment was considered 
effective by the absence of live lice by day 15 of 
treatment. All the observations and assessment of 
treatment were conducted by me under the 
supervision of a single expert dermatologist with 
having a minimum of five years’ experience. All of the 
above information including name, age, and gender 
were recorded in a predesigned proforma. 
Data Analysis: 
Data were analyzed in SPSS version 17. The mean age 
of the patient in the sample was calculated. The male 
to female ratio was determined in the sample. In both,  
groups, the frequency of patients having no live louse 
in the head on the 15th day was calculated. The 
frequency in both groups was compared by applying 
the chi-square test keeping a p-value≤ 0.05. 
 
Results 
 
The mean age of the patients was 9.25 ±1.27 years. The 
majority of the patients were presented with ≤10 years 
of age in both groups, i.e. 27 (90%) and 21 (70%) 
respectively. 
An insignificant difference was observed in the mean 
age in the between-group (p-value 0.482). (Table 1) 
There were 43 (71.7%) females and 17 (28.3%) males. 
The majority of the patients were females in both 
groups, i.e. 20 (66.7%) and 23 (76.7%) respectively.  
Overall, frequency of Pediculosis Capitis on the 15th 
day of treatment was found in 38 (63.3%) of the 
patients. (Figure 1) 
In the oral Ivermectin group, the majority of the 
patients had no Pediculosis Capitison 15th day of 
treatment 26 (86.7%) while in 1% Permethrin Shampoo 
18 (60%) of the patients had Pediculosis Capitison 15th 
day of treatment. (Figure 2) 
Efficacy was found significantly higher in oral 
Ivermectin group 26 (86.7%) as compared to 1%   
Permethrin Shampoo (P-value <0.001). (Table 2) 
Significant association of oral   Ivermectin group and 
1% Permethrin Shampoo was also observed in patients 
having ≤10 years of age (p-value <0.001), male gender 
(p-value=0.009), and female gender (p-value=0.005). 
(Table 3-4) 
 
 
Figure 1: Frequency of Pediculosis Capitis on 15th 
day of treatment 
 
 
 
Figure 2: Comparison of Pediculosis Capitison 15th 
day of treatment with respect to group 
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Table 1: Comparison of age of the patients with respect to groups (n= 60) 
 Group Mean ± SD P-value 95% CI 
Age of the patients 
(in years) 
Oral Ivermectin 9.13 ± 0.93 0.482 -0.89 to 0.42 
1% topical permethrin 9.36 ± 1.54 
Table 2: Comparison of age of the patients with respect to groups (n= 60) 
Group Efficacy Total P-value 
Yes No 
Oral Ivermectin 26 (86.7) 4 (13.3) 30 (100) <0.001 
1% topical permethrin 12 (40) 18 (60) 30 (100) 
Total 38 (63.3) 22 (36.7) 60 (100) 
 
Table 3: Efficacy between groups with respect to patient’s age 
Group Efficacy Total P-value 
Yes No 
Oral Ivermectin 24 (88.9) 
2 (66.7) 
3 (11.1) 
1 (33.3) 
27 (100) 
3 (100) 
<0.001 
 
  0.505 1% topical permethrin 8 (38.1) 
4 (44.4) 
13 (61.9) 
5 (55.6) 
21 (100) 
9 (100) 
Total 32 (66.7) 
6 (50) 
16 (33.3) 
6 (50) 
48 (100) 
12 (100) 
Age ≤10 years n=48 (represented in italic letter) 
Age ≥ 10 years n=12 (represented in Bold letter) 
 
Table 4: Efficacy between groups with respect to male & female gender 
Group Efficacy Total P-value 
Yes No 
Oral Ivermectin 9 (90) 
17 (85) 
1 (10) 
3 (15) 
10 (100) 
20 (100) 
0.009 
 
0.005 1% topical permethrin 2 (28.6) 
10 (43.5) 
5 (71.4) 
13 (56.5) 
7 (100) 
23 (100) 
Total 11 (64.7) 
27 (62.8) 
6 (35.3) 
16 (37.2) 
17 (100) 
43 (100) 
Male n= 17 (represented in bold letter) 
Female n=43 (represented in italic letter) 
 
Discussion 
 
Head lice (pediculosis capitis) are a highly contagious 
infestation and an infected person can commonly 
spread it through direct head to head contact. The 
head louse sucks blood from the human scalp 4-5 
times per day and injects saliva into the scalp which 
causes pruritis. The resulting repeated scratching leads 
to loss of hair integrity and secondary bacterial 
infections and reactive Cervical and Occipital 
Lymphadenopathy.6 
Head louse infestation can be easily diagnosed by 
inspecting the hair and scalp or by dry/wet combing.  
However, the superior method is wet combing.7 The 
nits can be seen in the occipital and postauricular 
regions.6 
Treatment options include manual removal (using a 
conditioner and a wet comb).8 Topical medications 
include neurotoxic drugs including permethrin, 
malathion, phenothrin and carbaryl,9 lindane,10 benzyl 
alcohol 5%,11 spinosad,12 dimeticone13, and oral 
medication such as ivermectin. 
Permethrin is a synthetic drug that acts as a 
neurotoxin.  It belongs to the pyrethroids neurotoxin 
family which affects voltage-sensitive Na+ channels of 
the nervous system of the insect, causing 
depolarization of the nerve resulting in 
hyperexcitation followed by muscle paralysis and 
196                                                                             Journal of Rawalpindi Medical College (JRMC); 2021; 25(2): 192-196  
ultimately death of the parasite. In a study performed 
by Ian F Burgess et al the efficacy of 1%, Permethrin 
was found out to be 14.9% when compared to 
Dimeticone.13 
Antiparasitic drug Ivermectin binds to glutamate-
gated Cl ion channels in invertebrates and interrupts 
neurotransmission can be used to treat conditions such 
as lymphatic filariasis, helminthiases, onchocerciasis, 
and ectoparasite infestations, mainly scabies.14 
The dose of oral Ivermectin in pediculosis capitis is 200 
mcg/kg, which is repeated after one week. Ivermectin 
is a safe drug however it can cross the blood-brain 
barrier and cause neurotoxicity in children with 
weight less than 15 kg and pregnant and breastfeeding 
mothers.15  A study conducted by Ameen et al on oral 
Ivermectin for pediculosis capitis showed efficacy of 
93%.14 
In this study, in the oral Ivermectin group, the 
majority of the patients presented with no Pediculosis 
Capitis on the 15th day of treatment 26 (86.7%) while in 
1% topical Permethrin 18 (60%) of the patients 
presented with Pediculosis Capitis on 15th day of 
treatment. Moreover, efficacy was found significantly 
higher in oral Ivermectin group 26 (86.7%) as 
compared to 1% topical Permethrin (P-value< 0.001). 
The mode of action of Permethrin (a pediculicide 
neurotoxin) is to derange the sodium channel current 
leading to delayed repolarization, and ultimately 
resulting in paralysis of the nerves of the muscle of the 
exoskeleton of lice which allows it to breath. 
The residual activity of Permethrin may last over 2 
weeks which is the only available pediculicide in this 
range. It is a pediculicidal as well as an ovicidal drug. 
Therefore, one application is usually sufficient. 
However, another course, 7 to 10 days later, maybe 
used which ensures a pediculosis clearance rate of 
about 95%. Reports of resistance to 1% Permethrin is 
available but the prevalence of this resistance is 
uncertain. 
Permethrin 5% topical solution is applied at night for 
scabies treatment. FDA initially approved Permethrin 
for the treatment of scabies but later also approved 1% 
Permethrin for the treatment of head lice. It is applied 
to the scalp and left on for several hours or overnight, 
and then it should be washed off. 
No case-control studies have reported efficacy to date. 
One study suggested that lice resistant to 1% 
permethrin will not succumb to higher concentrations. 
 
 
 
 
Conclusion 
  
Our study result showed that the efficacy of the oral 
Ivermectin group was considerably higher as 
compared to 1% Permethrin Shampoo 
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